Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) major shareholder Global Strategic Fund I. Venbio bought 416,666 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The stock was purchased at an average cost of $12.00 per share, for a total transaction of $4,999,992.00. Following the completion of the purchase, the insider now owns 1,936,637 shares of the company’s stock, valued at $23,239,644. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Artiva Biotherapeutics Stock Down 1.9 %
Shares of NASDAQ ARTV traded down $0.23 during mid-day trading on Monday, hitting $11.77. The stock had a trading volume of 342,563 shares. Artiva Biotherapeutics, Inc. has a 1 year low of $11.71 and a 1 year high of $16.00.
Further Reading
- Five stocks we like better than Artiva Biotherapeutics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- How to Find Undervalued Stocks
- Has This Leading Tech Stock Halted the AI Surge?
- Canada Bond Market Holiday: How to Invest and Trade
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.